Abstract
The chromosomal aberrations typical for prostate cancer have been quite well characterized by using molecular genetic tools, such as the analysis of loss of heterozygosity (LOH), comparative genomic hybridization (CGH), and the array-based CGH (aCGH). Consequently, the major challenge during recent years has been the identification of the individual genes targeted by these chromosomal alterations. Although some target genes, including the androgen receptor gene (AR) at Xq and the PTEN tumor suppressor gene at the 10q, are already known, most target genes are yet to be discovered. Overall, only a few genes have been found to be mutated in prostate cancer. The most common alterations of individual genes, detected so far, are hypermethylation of the GSTP1 gene, amplification of the AR gene, and mutations in the TP53 and PTEN genes. Because genetic alterations seem to point out the weak spots of cancer and have, thus, been used as markers for druggable targets in many other cancer types, it would be extremely important to carry out systematic mutation screening programs to find more genes that are frequently mutated also in prostate cancer.
Key Words
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
DeMarzo, A. M., Nelson, W. G., Isaacs, W. B., and Epstein, J. I. (2003). Pathological and molecular aspects of prostate cancer. Lancet 361, 955–964.
Arnold, J. T. and Isaacs, J. T. (2002). Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell’s fault. Endocr. Relat. Cancer 9, 61–73.
Sandberg, A. A. (1992). Chromosomal abnormalities and related events in prostate cancer. Hum. Pathol. 23, 368–380.
Kunimi, K., Bergerheim, U. S., Larsson, I. L., Ekman,.P, and Collins, V. P. (1991). Allelotyping of human prostatic adenocarcinoma. Genomics 11, 530–536.
Cunningham, J. M., Shan, A., Wick, M. J., et al. (1996). Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res. 56, 4475–4482.
Dumur, C. I., Dechsukhum, C., Ware, J. L., et al. (2003). Genome-wide detection of LOH in prostate cancer using human SNP microarray technology. Genomics 81, 260–269.
Lieberfarb, M. E., Lin, M., Lechpammer, M., et al. (2003). Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 63, 4781–4785.
Karan, D., Lin, M. F., Johansson, S. L., and Batra, S. K. (2003). Current status of the molecular genetics of human prostatic adenocarcinomas. Int. J. Cancer. 103, 285–293.
Bova, G. S., Carter, B. S., Bussemakers, M. J., et al. (1993). Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 53, 3869–3873.
Kagan, J., Stein, J., Babaian, R. J., et al. (1995). Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene 11, 2121–2126.
Oba, K., Matsuyama, H., Yoshihiro, S., et al. (2001). Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer. Cancer Genet. Cytogenet. 124, 20–26.
Emmert-Buck, M. R., Vocke, C. D., Pozzatti, R. O., et al. (1995). Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res. 55, 2959–2962.
He, W. W., Sciavolino, P. J., Wing, J., et al. (1997). A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics 43, 69–77.
Voeller, H. J., Augustus, M., Madike, V., Bova, G. S., Carter, K. C., and Gelmann, E. P. (1997). Coding region of NKX3.1, a prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57, 4455–4459.
Abdulkadir, S. A., Magee, J. A., Peters, T. J., et al. (2002). Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22, 1495–1503.
Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., et al. (1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13, 966–977.
Xu, J., Zheng, S. L., Komiya, A., et al. (2002). Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat. Genet. 32, 321–325.
Xu, J., Zheng, S. L., Komiya, A., et al. (2003). Common sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Am. J. Hum. Genet. 72, 208–212.
Miller, D. C., Zheng, S. L., Dunn, R. L., et al. (2003). Germ-line mutations of the macrophage scavenger receptor 1 gene: association with prostate cancer risk in African-American men. Cancer Res. 63, 3486–3489.
Nupponen, N. N., Wallen, M. J., Ponciano, D., et al. (2004). Mutational analysis of susceptibility genes RNASEL/ HPC1, ELAC2/HPC2, and MSR1 in sporadic prostate cancer. Genes Chromosomes Cancer 39, 119–125.
Li, C., Berx, G., Larsson, C., et al. (1999). Distinct deleted regions on chromosome segment 16q23-24 associated with metastases in prostate cancer. Genes Chromosomes Cancer 24, 175–182.
Elo, J. P., Harkonen, P., Kyllonen, A. P., et al. (1997). Loss of heterozygosity at 16q24.1-q24.2 is significantly associated with metastatic and aggressive behavior of prostate cancer. Cancer Res. 57, 3356–3359.
Elo, J. P., Harkonen, P., Kyllonen, A. P., Lukkarinen, O., and Vihko, P. (1999). Three independently deleted regions at chromosome arm 16q in human prostate cancer: allelic loss at 16q24.1-q24.2 is associated with aggressive behaviour of the disease, recurrent growth, poor differentiation of the tumour and poor prognosis for the patient. Br. J. Cancer 79, 156–160.
Suzuki, H., Komiya, A., Emi, M., et al. (1996). Three distinct commonly deleted regions of chromosome arm 16q in human primary and metastatic prostate cancers. Genes Chromosomes Cancer 17, 225–233.
Latil, A., Cussenot, O., Fournier, G., Driouch, K., and Lidereau, R. (1997). Loss of heterozygosity at chromosome 16q in prostate adenocarcinoma: identification of three independent regions. Cancer Res. 57, 1058–1062.
Frixen, U. H., Behrens, J., Sachs, M., et al. (1991). E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell. Biol. 113, 173–185.
Umbas, R., Schalken, J. A., Aalders, T. W., et al. (1992). Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res. 52, 5104–5109.
Umbas, R., Isaacs, W. B., Bringuier, P. P., et al. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54, 3929–3933.
Richmond, P. J., Karayiannakis, A. J., Nagafuchi, A., Kaisary, A. V., and Pignatelli, M. (1997). Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival. Cancer Res. 57, 3189–3193.
Rubin, M. A., Mucci, N. R., Figurski, J., Fecko, A., Pienta, K. J., and Day, M. L. (2001). E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology. Hum. Pathol. 32, 690–697.
Murant, S. J., Rolley, N., Phillips, S. M., Stower, M., and Maitland, N. J. (2000). Allelic imbalance within the Ecadherin gene is an infrequent event in prostate carcinogenesis. Genes Chromosomes Cancer 27, 104–109.
Sun, X., Frierson, H. F., Chen, C., et al. (2005). Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat. Genet. 37, 407–412.
Hyytinen, E. R., Frierson, H. F. Jr., Boyd, J. C., Chung, L. W., and Dong, J. T. (1999). Three distinct regions of allelic loss at 13q14, 13q21-22, and 13q33 in prostate cancer. Genes Chromosomes Cancer 25, 108–114.
Gray, I. C., Phillips, S. M., Lee, S. J., Neoptolemos, J. P., Weissenbach, J., and Spurr, N. K. (1995). Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 55, 4800–4803.
Lacombe, L., Orlow, I., Reuter, V. E., et al. (1996). Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int. J. Cancer 69, 110–113.
Li, J., Yen, C., Liaw, D., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947.
Steck, P. A., Pershouse, M. A., Jasser, S. A., et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356–362.
Li, D. M. and Sun H. (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res. 57, 2124–2129.
Kawamata, N., Park, D., Wilczynski, S., Yokota, J., and Koeffler, H. P. (1996). Point mutations of the Mxil gene are rare in prostate cancers. Prostate 29, 191–193.
Kuczyk, M. A., Serth, J., Bokemeyer, C., et al. (1998). The MXI1 tumor suppressor gene is not mutated in primary prostate cancer. Oncol. Rep. 5, 213–216.
Zenklusen, J. C., Thompson, J. C., Troncoso, P., Kagan, J., and Conti, C. J. (1994). Loss of heterozygosity in human primary prostate carcinomas: a possible tumor suppressor gene at 7q31.1. Cancer Res. 54, 6370–6373.
Latil, A., Cussenot, O., Fournier, G., Baron, J. C., and Lidereau, R. (1995). Loss of heterozygosity at 7q31 is a frequent and early event in prostate cancer. Clin. Cancer Res. 1, 1385–1389.
Takahashi, S., Shan, A. L., Ritland, S. R., et al. (1995). Frequent loss of heterozygosity at 7q31.1 in primary prostate cancer is associated with tumor aggressiveness and progression. Cancer Res. 55, 4114–4119.
Zenklusen, J. C., Hodges, L. C., LaCava, M., Green, E. D., and Conti, C. J. (2000). Definitive functional evidence for a tumor suppressor gene on human chromosome 7q31.1 neighboring the Fra7G site. Oncogene 19, 1729–1733.
Alcaraz, A., Takahashi, S., Brown, J. A., et al. (1994). Aneuploidy and aneusomy of chromosome 7 detected by fluorescence in situ hybridization are markers of poor prognosis in prostate cancer. Cancer Res. 54, 3998–4002.
Visakorpi, T., Hyytinen, E., Kallioniemi, A., Isola, J., and Kallioniemi, O. P. (1994). Sensitive detection of chromosome copy number aberrations in prostate cancer by fluorescence in situ hybridization. Am. J. Pathol. 145, 624–630.
Bandyk, M. G., Zhao, L., Troncoso, P., et al. (1994). Trisomy 7: a potential cytogenetic marker of human prostate cancer progression. Genes Chromosomes Cancer 9, 19–27.
Visakorpi, T., Kallioniemi, A. H., Syvanen, A. C., et al. (1995). Genetic changes in primary and recurrent prostate cancer by comparative genomic hybridization. Cancer Res. 55, 342–347.
Wang, R. Y., Troncoso, P., Palmer, J. L., El-Naggar, A. K., and Liang, J. C. (1996). Trisomy 7 by dual-color fluorescence in situ hybridization: a potential biological marker for prostate cancer progression. Clin. Cancer Res. 2, 1553–1558.
Cui, J., Deubler, D. A., Rohr, L. R., et al. (1998). Chromosome 7 abnormalities in prostate cancer detected by dualcolor fluorescence in situ hybridization. Cancer Genet. Cytogenet. 107, 51–60.
Alers, J. C., Krijtenburg, P. J., Vis, A. N., et al. (2001). Molecular cytogenetic analysis of prostatic adenocarcinomas from screening studies: early cancers may contain aggressive genetic features. Am. J. Pathol. 158, 399–406.
Nupponen, N. N., Kakkola, L., Koivisto, P., and Visakorpi, T. (1998). Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am. J. Pathol. 153, 141–148.
Galbiati, F., Volonte, D., Engelman, J. A., et al. (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J. 17, 6633–6648.
Zhang, W., Razani, B., Altschuler, Y., et al. (2000). Caveolin-1 inhibits epidermal growth factor-stimulated lamellipod extension and cell migration in metastatic mammary adenocarcinoma cells (MTLn3). Transformation suppressor effects of adenovirus-mediated gene delivery of caveolin-1. J. Biol. Chem. 275, 20717–20725.
Bender, F. C., Reymond, M. A., Bron, C., and Quest, A. F. (2000). Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60, 5870–5878.
Wiechen, K., Diatchenko, L., Agoulnik, A., et al. (2001). Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159, 1635–1643.
Wiechen, K., Sers, C., Agoulnik, A., et al. (2001). Down-regulation of caveolin-1, a candidate tumor suppressor gene, in sarcomas. Am. J. Pathol. 158, 833–839.
Yang, G., Truong, L. D., Wheeler, T. M., and Thompson, T. C. (1999). Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker. Cancer Res. 59, 5719–5723.
Nasu, Y., Timme, T. L., Yang, G., et al. (1998). Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells. Nat. Med. 4, 1062–1064.
Tahir, S. A., Yang, G., Ebara, S., et al. (2001). Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res. 61, 3882–3885.
Li, L., Yang, G., Ebara, S., et al. (2001). Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res. 61, 4386–4392.
Cooney, K. A., Wetzel, J. C., Consolino, C. M., and Wojno, K. J. (1996). Identification and characterization of proximal 6q deletions in prostate cancer. Cancer Res. 56, 4150–4153.
Srikantan, V., Sesterhenn, I. A., Davis, L., et al. (1999). Allelic loss on chromosome 6Q in primary prostate cancer. Int. J. Cancer. 84, 331–335.
Hyytinen, E. R., Saadut, R., Chen, C., et al. (2002). Defining the region(s) of deletion at 6q16-q22 in human prostate cancer. Genes Chromosomes Cancer 34, 306–312.
Konishi, N., Nakamura, M., Kishi, M., et al. (2003). Genetic mapping of allelic loss on chromosome 6q within heterogeneous prostate carcinoma. Cancer Sci. 94, 764–768.
Ueda, T., Komiya, A., Emi, M., et al. (1997). Allelic losses on 18q21 are associated with progression and metastasis in human prostate cancer. Genes Chromosomes Cancer 20, 140–147.
Padalecki, S. S., Troyer, D. A., Hansen, M. F., et al. (2000). Identification of two distinct regions of allelic imbalance on chromosome 18Q in metastatic prostate cancer. Int. J. Cancer 85, 654–658.
Latil, A., Pesche, S., Valeri, A., Fournier, G., Cussenot, O., and Lidereau, R. (1999). Expression and mutational analysis of the MADR2/Smad2 gene in human prostate cancer. Prostate 40, 2225–2231.
Yin, Z., Babaian, R. J., Troncoso, P., et al. (2001). Limiting the location of putative human prostate cancer tumor suppressor genes on chromosome 18q. Oncogene 20, 2273–2280.
Nupponen, N. N. and Visakorpi, T. (2000). Molecular cytogenetics of prostate cancer. Microsc. Res. Tech. 51, 456–463.
Cher, M. L., Bova, G. S., Moore, D. H., et al. (1996). Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res. 56, 3091–3102.
Alers, J. C., Rochat, J., Krijtenburg, P. J., et al. (2000). Identification of genetic markers for prostatic cancer progression. Lab. Invest. 80, 931–942.
van Dekken, H., Alers, J. C., Damen, I. A., et al. (2003). Genetic evaluation of localized prostate cancer in a cohort of forty patients: gain of distal 8q discriminates between progressors and nonprogressors. Lab. Invest. 83, 789–796.
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., et al. (2003). Myc-driven murine prostate cancer shares molecular features with human prostate tumors. Cancer Cell 4, 223–238.
Jenkins, R. B., Qian, J., Lieber, M. M., and Bostwick, D. G. (1997). Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res. 57, 524–531.
Nupponen, N. N., Porkka,.K, Kakkola, L., et al. (1999). Amplification and overexpression of p40 subunit of eukaryotic translation initiation factor 3 in breast and prostate cancer. Am. J. Pathol. 154, 1777–1783.
Sato, K., Qian, J., Slezak, J. M., et al. (1999) Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma. J. Natl. Cancer. Inst. 91, 1574–1580.
Savinainen, K. J., Linja, M. J., Saramaki, O. R., et al. (2004). Expression and copy number analysis of TRPS1, EIF3S3 and MYC genes in breast and prostate cancer. Br. J. Cancer 90, 1041–1046.
Porkka, K. P., Tammela, T. L., Vessella, R. L., and Visakorpi, T. (2004). RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer 39, 1–10.
Saramaki, O., Willi, N., Bratt, O., et al. (2001). Amplification of EIF3S3 gene is associated with advanced stage in prostate cancer. Am. J. Pathol. 159, 2089–2094.
Asano,.K, Vornlocher, H. P., Richter-Cook, N. J., Merrick, W. C., Hinnebusch, A. G., and Hershey, J. W. (1997). Structure of cDNAs encoding human eukaryotic initiation factor 3 subunits. Possible roles in RNA binding and macromolecular assembly. J. Biol. Chem. 272, 27,042–27,052.
Nasmyth, K., Peters, J. M., and Uhlmann, F. (2000). Splitting the chromosome: cutting the ties that bind sister chromatids. Science 288, 1379–1385.
Hirano, T. (2000). Chromosome cohesion, condensation, and separation. Annu. Rev. Biochem. 69, 115–144.
Chen, F., Kamradt, M., Mulcahy, M., et al. (2002). Caspase proteolysis of the cohesin component RAD21 promotes apoptosis. J. Biol. Chem. 277, 16,775–16,781.
Pati, D., Zhang, N., and Plon, S. E. (2002). Linking sister chromatid cohesion and apoptosis: role of Rad21. Mol. Cell. Biol. 22, 8267–8277.
Reiter, R. E., Gu, Z., Watabe, T., et al. (1998). Prostate stem cell antigen: a cell surface marker overexpressed in prostate cancer. Proc. Natl. Acad. Sci. USA 95, 1735–1740.
Chang, G. T., Steenbeek, M., Schippers, E., et al. (2000). Characterization of a zinc-finger protein and its association with apoptosis in prostate cancer cells. J. Natl. Cancer. Inst. 92, 1414–1421.
Gu, Z., Thomas, G., Yamashiro, J., et al. (2000). Prostate stem cell antigen (PSCA) expression increases with high gleason score, advanced stage and bone metastasis in prostate cancer. Oncogene 19, 1288–1296.
Ross, S., Spencer, S. D., Holcomb, I., et al. (2002). Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 62, 2546–2553.
Chang, G. T., Blok, L. J., Steenbeek, M., et al. (1997). Differentially expressed genes in androgen-dependent and-independent prostate carcinomas. Cancer Res. 57, 4075–4081.
Porkka, K., Saramaki, O., Tanner, M., and Visakorpi, T. (2002). Amplification and overexpression of Elongin C gene discovered in prostate cancer by cDNA microarrays. Lab. Invest. 82, 629–637.
Wang, R., Xu, J., Saramaki, O., et al. (2004). PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res. 64, 1589–1594.
Rubin, M. A., Varambally, S., Beroukhim, R., et al. (2004). Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res. 64, 3814–3822.
Aso, T., Lane, W. S., Conaway, J. W., and Conaway, R. C. (1995). Elongin (SIII): a multisubunit regulator of elongation by RNA polymerase II. Science 269, 1439–1443.
Duan, D. R., Pause, A., Burgess, W. H., et al. (1995). Inhibition of transcription elongation by the VHL tumor suppressor protein. Science 269, 1402–1406.
Kibel, A., Iliopoulos, O., DeCaprio, J. A., and Kaelin, W. G., Jr. (1995). Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C. Science 269, 1444–1446.
Stebbins, C. E., Kaelin, W. G., Jr, and Pavletich, N. P. (1999). Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function. Science 284, 455–461.
Kaelin, W. G., Jr. (2002). Molecular basis of the VHL hereditary cancer syndrome. Nat. Rev. Cancer 2, 673–682.
Zhong, H., Agani, F., Baccala, A. A., et al. (1998) Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res. 58, 5280–5284.
Kamura, T., Sato, S., Haque, D., et al. (1998). The Elongin BC complex interacts with the conserved SOCS-box motif present in members of the SOCS, ras, WD-40 repeat, and ankyrin repeat families. Genes Dev. 12, 3872–3881.
Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., von Eschenbach, A. C., and Chung, L. W. (1995). c-met protooncogene expression in benign and malignant human prostate tissues. J. Urol. 154, 293–298.
Humphrey, P. A., Zhu, X., Zarnegar, R., et al. (1995). Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 147, 386–396.
Watanabe, M., Fukutome, K., Kato, H., et al. (1999). Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 141, 173–178.
Knudsen, B. S., Gmyrek, G. A., Inra, J., et al. (2002). High expression of the Met receptor in prostate cancer metastasis to bone. Urology 60, 1113–1117.
Varambally, S., Dhanasekaran, S. M., Zhou, M., et al. (2002). The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624–629.
Rhodes, D. R., Sanda, M. G., Otte, A. P., Chinnaiyan, A. M., and Rubin, M. A. (2003). Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer. J. Natl. Cancer Inst. 95, 661–668.
Foster, C. S., Falconer, A., Dodson, A. R., et al. (2004). Transcription factor E2F3 overexpressed in prostate cancer independently predicts clinical outcome. Oncogene 23, 5871–5879.
Bracken, A. P., Pasini, D., Capra, M., Prosperini, E., Colli, E., and Helin, K. (2003). EZH2 is downstream of the pRBE2F pathway, essential for proliferation and amplified in cancer. EMBO J. 22, 5323–5335.
Nupponen, N. N., Isola, J., and Visakorpi, T. (2000). Mapping the amplification of EIF3S3 in breast and prostate cancer. Genes Chromosomes Cancer 28, 203–210.
Clark, J., Edwards, S., Feber, A., et al. (2003). Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene 22, 1247–1452.
Wolf, M., Mousses, S., Hautaniemi, S., et al. (2004). High-resolution analysis of gene copy number alterations in human prostate cancer using CGH on cDNA microarrays: impact of copy number on gene expression. Neoplasia 6, 240–247.
van Dekken, H. Paris, P.L., Albertson, D. G., et al. (2004). Evaluation of genetic patterns in different tumor areas of intermediate-grade prostatic adenocarcinomas by high-resolution genomic array analysis. Genes Chromosomes Cancer 39, 249–256.
Paris, P. L., Albertson, D. G., Alers, J. C., et al. (2003). High-resolution analysis of paraffin-embedded and formalinfixed prostate tumors using comparative genomic hybridization to genomic microarrays. Am. J. Pathol. 162, 763–770.
Paris, P. L., Andaya, A., Fridlyand, J., et al. (2004). Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum. Mol. Genet. 13, 1303–1313.
Zhao, H., Kim, Y., Wang, P., et al. (2005). Genome-wide characterization of gene expression variations and DNA copy number changes in prostate cancer cell lines. Prostate 63, 187–197.
Bookstein, R., MacGrogan, D., Hilsenbeck, S. G., Sharkey, F., and Allred, D. C. (1993). p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res. 53, 3369–3373.
Visakorpi, T., Kallioniemi, O. P., Heikkinen, A., Koivula, T., and Isola, J. (1992). Small subgroup of aggressive, highly proliferative prostatic carcinomas defined by p53 accumulation. J. Natl. Cancer Inst. 84, 883–887.
Navone, N. M., Troncoso, P., Pisters, L. L., et al. (1993). p53 protein accumulation and gene mutation in the progression of human prostate carcinoma. J. Natl. Cancer Inst. 85, 1657–1669.
Feilotter, H. E., Nagai, M. A., Boag, A. H., Eng, C., and Mulligan, L. M. (1998). Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene 16, 1743–1748.
Pesche, S., Latil, A., Muzeau, F., et al. (1998). PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 16, 2879–2883.
Dong, J. T., Sipe, T. W., Hyytinen, E. R., et al. (1998). PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene 17, 1979–1982.
Vlietstra, R. J., van Alewijk, D. C., Hermans, K. G., van Steenbrugge, G. J., and Trapman, J. (1998). Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res. 58, 2720–2723.
Suzuki, H., Freije, D., Nusskern, D. R., et al. (1998). Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58, 204–209.
Fernandez, M. and Eng, C. (2002). The expanding role of PTEN in neoplasia: a molecule for all seasons? Clin. Cancer Res. 8, 1695–1698.
Kwabi-Addo, B., Giri, D., Schmidt, K., et al. (2001). Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA 98, 11,563–11,568.
Kim, M. J., Cardiff, R. D., Desai, N., et al. (2002). Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA 99, 2884–2889.
Ayala, G., Thompson, T., Yang, G., et al. (2004). High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin. Cancer Res. 10, 6572–6578.
Neshat, M. S., Mellinghoff, I. K., Tran, C., et al. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10,314–10,319.
Culig, Z., Klocker, H., Bartsch, G., and Hobisch, A. (2001). Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. Am. J. Pharmacogenomics 1, 241–249.
Wallen, M. J., Linja, M., Kaartinen, K., Schleutker, J., and Visakorpi, T. (1999). Androgen receptor gene mutations in hormone-refractory prostate cancer. J. Pathol. 189, 559–563.
Taplin, M. E., Bubley, G. J., Shuster, T. D., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393–1398.
Haapala, K., Hyytinen, E. R., Roiha, M., et al. (2001). Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Lab. Invest. 81, 1647–1651.
Hara, T., Miyazaki, J., Araki, H., et al. (2003). Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 63, 149–153.
Visakorpi, T., Hyytinen, E., Koivisto, P., et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 9, 401–406.
Elo, J. P. and Visakorpi, T. (2001). Molecular genetics of prostate cancer. Ann. Med. 33, 130–141.
Palmberg, C., Koivisto, P., Kakkola, L., Tammela, T. L. J., Kallioniemi, O. P., and Visakorpi, T. (2000). Androgen receptor gene amplification at the time of primary progression predicts response to combined androgen blockade as a second-line therapy in advanced prostate cancer. J. Urology 164, 1992–1995.
Linja, M. J., Savinainen, K. J., Saramäki, O. R., Tammela, T. L. J., Vessella, R. L., and Visakorpi, T. (2001). Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550–3555.
Latil, A., Bieche, I., Vidaud, D., et al. (2001). Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays. Cancer Res. 61, 1919–1926.
Chen, C. D., Welsbie, D. S., Tran, C., et al. (2004). Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33–39.
Nakayama, M., Bennett, C. J., Hicks, J. L., et al. (2003). Hypermethylation of the human glutathione S-transferase-pi gene (GSTP1) CpG island is present in a subset of proliferative inflammatory atrophy lesions but not in normal or hyperplastic epithelium of the prostate: a detailed study using laser-capture microdissection. Am. J. Pathol. 163, 923–933.
Lee, W. H., Morton, R. A., Epstein, J. I., et al. (1994). Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl. Acad. Sci. USA 91, 11,733–11,737.
Goessl, C., Krause, H., Muller, M., et al. (2000). Fluorescent methylation-specific polymerase chain reaction for DNAbased detection of prostate cancer in bodily fluids. Cancer Res. 60, 5941–5945.
Narla, G., Heath, K. E., Reeves, H. L., et al. (2001). KLF6, a candidate tumor suppressor gene mutated in prostate cancer. Science 294, 2563–2566.
Chen, C., Hyytinen, E. R., Sun, X., et al. (2003). Deletion, mutation, and loss of expression of KLF6 in human prostate cancer. Am. J. Pathol. 162, 1349–1354.
Muhlbauer, K. R., Grone, H. J., Ernst, T., et al. (2003). Analysis of human prostate cancers and cell lines for mutations in the TP53 and KLF6 tumour suppressor genes. Br. J. Cancer 89, 687–990.
Huusko, P., Ponciano-Jackson, D., Wolf, M., et al. (2004). Nonsense-mediated decay microarray analysis identifies mutations of EPHB2 in human prostate cancer. Nat. Genet. 36, 979–983.
Kullander, K. and Klein, R. (2002). Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell. Biol. 3, 475–486.
Druker, B. J., Talpaz, M., Resta, D. J., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037.
Slamon, D. J., Leyland-Jones, B., Shak, S., et al. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783–792.
Lynch, T. J., Bell, D. W., Sordella, R., et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129–2139.
Paez, J. G., Janne, P. A., Lee, J. C., et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497–1500.
Bykov, V. J., Issaeva, N., Shilov, A., et al. (2002). Restoration of the tumor suppressor function to mutant p53 by a lowmolecular-weight compound. Nat. Med. 8, 282–288.
Neshat, M. S., Mellinghoff, I. K., Tran, C.,et al. (2001). Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl. Acad. Sci. USA 98, 10,314–10,319.
Podsypanina, K., Lee, R. T., Politis, C., et al. (2001). An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/-mice. Proc. Natl. Acad. Sci. USA 98, 10,320–10,325.
Futreal, P. A., Coin, L., Marshall, M., et al. (2004). A census of human cancer genes. Nat. Rev. Cancer 4, 177–183.
Asatiani, E., Huang, W. X., Wang, A., et al. (2005). Deletion, methylation, and expression of the NKX3.1 suppressor gene in primary human prostate cancer. Cancer Res. 65, 1164–1173.
Saramäki, O. R., Tammela, T. L., Martikainen, P. M., et al. (2006). The gene for polycomb group protein enhancer of zesle homolog 2 (EZH2) is amplified in late stage prostate cancer. Genes Chromosomes Cancer 45, 639–645.
Saramäki, O. R., Porkka, K. P., Vessella, R. L., et al. (2006). Genetic aberrations in prostate cancer by microarray analysis. Int. J. Cancer 119, 1322–1329.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this chapter
Cite this chapter
Porkka, K.P., Visakorpi, T. (2007). Somatic Alterations in Prostate Cancer Progression. In: Chung, L.W.K., Isaacs, W.B., Simons, J.W. (eds) Prostate Cancer. Contemporary Cancer Research. Humana Press. https://doi.org/10.1007/978-1-59745-224-3_15
Download citation
DOI: https://doi.org/10.1007/978-1-59745-224-3_15
Publisher Name: Humana Press
Print ISBN: 978-1-58829-696-2
Online ISBN: 978-1-59745-224-3
eBook Packages: MedicineMedicine (R0)